Weekly signal · MRNA · Healthcare

Moderna Inc (MRNA) extends 12-week surge to 129.0%

The biotechnology stock closed at $154.04, with shorter-term gains still positive and the weekly trend screen active.

Moderna Inc
Latest154.04 USD
1W move7.0%
Volume0.9x
TrendActive
Moderna biotechnology lab materials with a financial chart screen in the background.

Market update

What happened

Moderna Inc (MRNA) rose 7.0% for the week ended Sept. 18, closing at $154.04. The move added to a 6.1% four-week gain and left the stock up 129.0% over 12 weeks.

The confirming evidence is strong but not uniform. Market Dynamics showed positive pressure at 1.61 and Relative Strength stood at 162.4, while latest weekly volume of 67.6 million shares remained below the 13-week average of 77.8 million. The weekly price path over 52 weeks frames the move as a longer-running rebound rather than an intraday swing.

Continue your research

Explore MRNA across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

MRNA coverage

Moderna’s 146% four-week move puts the Fair Value gap at 131%

Moderna added 5.5% in the latest week and remains one of biotechnology’s strongest short-term performers, but the move is now far above its weekly Trend Line and Sharemaestro Fair Value while volume confirmation is only moderate.

Evidence context